MX2016016119A - Compuestos quimicos y composiciones farmaceuticas que inhiben el virus de la hepatitis c y sus aplicaciones. - Google Patents

Compuestos quimicos y composiciones farmaceuticas que inhiben el virus de la hepatitis c y sus aplicaciones.

Info

Publication number
MX2016016119A
MX2016016119A MX2016016119A MX2016016119A MX2016016119A MX 2016016119 A MX2016016119 A MX 2016016119A MX 2016016119 A MX2016016119 A MX 2016016119A MX 2016016119 A MX2016016119 A MX 2016016119A MX 2016016119 A MX2016016119 A MX 2016016119A
Authority
MX
Mexico
Prior art keywords
virus
compounds
hepatitis
pharmaceutical compositions
hcv
Prior art date
Application number
MX2016016119A
Other languages
English (en)
Inventor
Yun James Zhan Zheng-
Original Assignee
Ab Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Pharma Ltd filed Critical Ab Pharma Ltd
Publication of MX2016016119A publication Critical patent/MX2016016119A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Ofrecen una clase de compuestos para inhibir el virus de hepatitis C(HCV), sus estereoisómeros, tautómeros, Isómeros isotópicos, hidratos, profármacos esterificados o amidados, sales aceptables farmacéuticamente, composición farmacéutica y su aplicación, y las aplicaciones de las mezcla con uno o más de estos ingredientes para la preparación de los fármacos inhibidores de VHC, los dichos compuestos pueden inhibir con eficacia el virus de hepatitis C NS5A, y se pueden utilizar para la preparación de los fármacos para la prevención y / o tratamiento de la infección por virus de hepatitis C (HCV-NS5A) (ver Fórmulas).
MX2016016119A 2014-06-06 2014-12-03 Compuestos quimicos y composiciones farmaceuticas que inhiben el virus de la hepatitis c y sus aplicaciones. MX2016016119A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2014/079386 WO2015184644A1 (zh) 2014-06-06 2014-06-06 抑制丙肝病毒的化合物、药物组合物及其应用
PCT/CN2014/092902 WO2015184753A1 (zh) 2014-06-06 2014-12-03 抑制丙肝病毒的化合物、药物组合物及其应用

Publications (1)

Publication Number Publication Date
MX2016016119A true MX2016016119A (es) 2017-03-28

Family

ID=54765978

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016119A MX2016016119A (es) 2014-06-06 2014-12-03 Compuestos quimicos y composiciones farmaceuticas que inhiben el virus de la hepatitis c y sus aplicaciones.

Country Status (18)

Country Link
EP (1) EP3153515B1 (es)
JP (1) JP6523440B2 (es)
KR (1) KR102025415B1 (es)
AU (1) AU2014396578C1 (es)
BR (1) BR112016028616B1 (es)
CA (1) CA2951317C (es)
DK (1) DK3153515T3 (es)
ES (1) ES2829920T3 (es)
HU (1) HUE051356T2 (es)
IL (1) IL249403B (es)
MX (1) MX2016016119A (es)
MY (1) MY178515A (es)
PE (1) PE20170266A1 (es)
PL (1) PL3153515T3 (es)
PT (1) PT3153515T (es)
RU (1) RU2671194C2 (es)
SG (1) SG11201610453SA (es)
WO (2) WO2015184644A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109232612A (zh) * 2017-07-11 2019-01-18 周龙兴 抑制丙肝病毒的化合物、药物组合物及其用途
CN111118073B (zh) * 2019-12-27 2022-02-15 宜昌东阳光生化制药有限公司 酶法合成依米他韦中间体的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101558059B (zh) * 2006-08-11 2014-12-03 百时美施贵宝公司 丙型肝炎病毒抑制剂
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
SI2242752T1 (sl) * 2008-02-13 2013-03-29 Bristol-Myers Squibb Company Imidazolil bifnil imidazoli kot hepatitis c virusni inhibitorji
US7704992B2 (en) * 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8147818B2 (en) * 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010062821A1 (en) * 2008-11-28 2010-06-03 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
WO2010096462A1 (en) * 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Linked diimidazole derivatives
SG10201402969QA (en) * 2009-03-27 2014-09-26 Merck Sharp & Dohme Inhibitors of hepatitis c virus replication
KR101546119B1 (ko) * 2009-05-13 2015-08-20 길리애드 파마셋 엘엘씨 항바이러스 화합물
MY159958A (en) * 2009-12-18 2017-02-15 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
KR20120130173A (ko) * 2009-12-24 2012-11-29 버텍스 파마슈티칼스 인코포레이티드 플라비바이러스 감염을 치료 또는 예방하기 위한 유사체들
EP2575866A4 (en) * 2010-05-24 2013-10-16 Presidio Pharmaceuticals Inc HCV NS5A INHIBITORS
US8778938B2 (en) * 2010-06-04 2014-07-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US20130310427A1 (en) * 2010-06-09 2013-11-21 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a protein
US20120195857A1 (en) * 2010-08-12 2012-08-02 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
AR083711A1 (es) * 2010-11-17 2013-03-20 Gilead Sciences Inc Compuestos heterociclicos utiles en el tratamiento de la hepatitis c
US9303061B2 (en) * 2011-07-09 2016-04-05 Sunshine Luke Pharma Co., Ltd. Spiro compounds as Hepatitis C virus inhibitors
CN103848819B (zh) * 2012-11-29 2017-04-12 广东东阳光药业有限公司 作为丙型肝炎抑制剂的螺环化合物、药物组合物及它们在药物中的应用
US9334291B2 (en) * 2013-06-06 2016-05-10 AB Pharma Ltd. Antiviral compounds highly effective as HCV-NS5A inhibitor
JP2017513852A (ja) * 2014-04-15 2017-06-01 コクリスタル ファーマ，インコーポレイテッド Ｃ型肝炎ウイルスの強力及び選択的な阻害剤

Also Published As

Publication number Publication date
DK3153515T3 (da) 2020-11-09
BR112016028616A8 (pt) 2021-07-20
RU2016151193A (ru) 2018-07-17
MY178515A (en) 2020-10-15
EP3153515A4 (en) 2018-07-25
KR20170005382A (ko) 2017-01-12
PL3153515T3 (pl) 2021-03-08
KR102025415B1 (ko) 2019-09-25
EP3153515A1 (en) 2017-04-12
WO2015184753A1 (zh) 2015-12-10
CA2951317A1 (en) 2015-12-10
HUE051356T2 (hu) 2021-03-01
AU2014396578A1 (en) 2017-01-19
ES2829920T3 (es) 2021-06-02
BR112016028616A2 (pt) 2017-08-22
BR112016028616B1 (pt) 2021-10-05
AU2014396578C1 (en) 2019-04-11
WO2015184644A1 (zh) 2015-12-10
RU2671194C2 (ru) 2018-10-30
SG11201610453SA (en) 2017-02-27
JP2017521484A (ja) 2017-08-03
IL249403A0 (en) 2017-02-28
PT3153515T (pt) 2020-11-11
AU2014396578B2 (en) 2018-11-22
PE20170266A1 (es) 2017-04-14
JP6523440B2 (ja) 2019-05-29
CA2951317C (en) 2019-10-01
RU2016151193A3 (es) 2018-07-17
EP3153515B1 (en) 2020-08-12
IL249403B (en) 2021-01-31

Similar Documents

Publication Publication Date Title
PH12018501736A1 (en) Tetracyclic pyridone compounds as antivirals
PH12018550148A1 (en) Hepatitis b antiviral agents
PH12018550201A1 (en) Hepatitis b antiviral agents
MX2019003525A (es) Moduladores alostericos de proteina nucleo de hepatitis b.
EA026667B9 (ru) Фармацевтическая композиция для лечения вируса гепатита с
JOP20180008A1 (ar) مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
MX2017008720A (es) Derivados y metodos para tratamiento de las infecciones por hepatitis b.
NZ703064A (en) Inhibitors of hepatitis c virus
TN2017000521A1 (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
IN2014MN02658A (es)
PH12014502739A1 (en) Macrocyclic inhibitors of flaviviridae viruses
TN2017000374A1 (en) TGF-β INHIBITORS
NZ703040A (en) Macrocyclic inhibitors of flaviviridae viruses
MY187617A (en) Bridged ring compounds as hepatitis c virus (hcv) inhibitors and pharmaceutical applications thereof
EA201791903A1 (ru) β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-C-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ
MX354676B (es) Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv).
MY179605A (en) Use of benzimidazole-proline derivatives
PH12016502039A1 (en) Potent and selective inhibitors of hepatitis c virus
MX2015013224A (es) Inhibidores macrociclicos y biciclicos del virus de la hepatitis c.
PH12017501687A1 (en) Inhibitors of hepatitis c virus polymerase
BR112014015582A2 (pt) compostos antivirais
MX2016016119A (es) Compuestos quimicos y composiciones farmaceuticas que inhiben el virus de la hepatitis c y sus aplicaciones.
MX2018002177A (es) Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo.
NZ726343A (en) Antiviral compounds
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.

Legal Events

Date Code Title Description
FG Grant or registration